AbVitro, Juno Therapeutics deal

Juno acquired AbVitro, gaining AbVitro’s high throughput, single-cell sequencing platform that enables identification of natively paired T cell receptors (TCRs) and chimeric antigen receptor (CAR) T cell binders. Juno said it will use AbVitro’s technology to discover antigen targets, analyze immune responses to cancer and monitor the immune system during treatment. Juno also said it has entered an agreement in principle to grant Celgene Corp. (NASDAQ:CELG; Summit, N.J.) a license to a subset of the AbVitro technology and options to gain rights to potential products resulting from the technology. ...